Could Genetically Engineered Humans Become a Reality?
By Robert King,
Washington Examiner
| 04. 30. 2015
[Quotes CGS's Marcy Darnovsky]
Untitled Document
Science is closer to creating genetically engineered human beings, and the advances in technology are sparking ethical arguments over making "a new kind of person."
The National Institutes of Health said Wednesday it would not fund any research into the gene editing of human embryos. The decision comes after Chinese researchers announced last week results from the first study to edit human embryo genes.
Gene editing, as the term implies, enables a scientist to cut DNA from a genome and insert it into another genome.
Theoretically an edited human embryo could then be implanted in a woman's uterus.
The goal is to edit the group of cells called the germline that could hand down diseases from one generation to the next. Researchers hope to prevent inherited diseases such as cystic fibrosis or sickle cell anemia from being passed on from a parent to a child.
The Chinese study was not successful. Scientists missed targets to place the DNA and discovered unknown mutations to cells.
However, the experiment has renewed talk in the scientific community of whether such research...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...